by Jakub Jarolím, Business Intelligence Department
Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).
SOTIO Biotech
7/6/2024
May 2024 Biotechnology: Review of news from the most innovative therapeutic areas and the business development transactions
Market
Fed voted to hold the target rate unchanged again, yet the NBI added 6 % during May
During its May meeting, the Fed voted to hold policy rates steady for the sixth consecutive time, leaving the target rate at 5.25% to 5.5%. It also stated it will likely take the Fed to gain confidence that the economy is on a sustainable path toward 2% inflation. Yet the NBI added 6 % during May.
Interleukin-15 and Interleukin-2
Mural Oncology presented clinical data from ARTISTRY-3 trial ahead of ASCO
Mural shared data from ARTISTRY-3 trial evaluating the effects of less frequent intravenous dosing (LFIV) of nemvaleukin alfa in advance of ASCO meeting. Nemvaleukin is an engineered IL-2 cytokine designed to capture and expand the therapeutic benefits of high-dose native IL-2 while mitigating the cytokine’s hallmark toxicities.
Antibody-Drug Conjugates
ADCT announced initial data from Phase 2 of Zynlonta in marginal zone lymphoma
ADCT announced that initial data from an investigator-initiated Phase 2 clinical trial evaluating Zynlonta demonstrated a high response rate in patients with relapsed or refractory (r/r) marginal zone lymphoma (MZL). The 50-patient single-arm, open-label Phase 2 multicenter study is currently being conducted at the Sylvester Comprehensive Cancer Center at University of Miami and City of Hope.
Cell Therapies
FDA approved Brayanzi for patients with relapsed or refractory follicular lymphoma
BMS announced the FDA has granted accelerated approval for Breyanzi (liso-cel), a CD19-directed CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Other Innovative Treatment Areas
Merck announced Phase 3 trial met OS endpoint as first-line treatment of HER2+ gastric cancer
Merck & Co. announced that the Phase 3 KEYNOTE-811 trial evaluating Keytruda in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy met its dual primary endpoint of OS for the first-line treatment of patients with HER2-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Sdílet na sociálních sítích